Neil P. Shah, Dong-Wook Kim, Hagop Kantarjian, Philippe Rousselot, Pedro Enrique Dorlhiac Llacer, Alicia Enrico, Jorge Vela-Ojeda, Richard T. Silver, Hanna Jean Khoury, Martin C. Müller, Alexandre Lambert, Yousif Matloub and Andreas Hochhaus (2010) “Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib”, Haematologica. Pavia, Italy, 95(2), pp. 232-240. doi: 10.3324/haematol.2009.011452.